Nonantifungal clinical drug interventions and human-commensal fungi: What are we selecting?

Future Microbiology

Volumn 8, Issue 7, 2013, Pages 813-816

  Hull, Claire M ^a   Purdy, Nicola J ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

adaptation; antifungal; Candida; clinical; commensal; drug resistance; mmunocompromised; stress; xenobiotic

Indexed keywords

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS FUMIGATUS; CHEMICAL STRESS; CHROMOSOMAL INSTABILITY; DISEASE COURSE; DRUG DESIGN; DRUG TRANSPORT; FUNGAL MENINGITIS; FUNGUS; FUNGUS GROWTH; GAIN OF FUNCTION MUTATION; GRAFT RECIPIENT; HEALTH CARE PRACTICE; HUMAN COMMENSAL FUNGUS; IN VITRO STUDY; LONG TERM EXPOSURE; LOSS OF FUNCTION MUTATION; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; STEROL ANALYSIS;

ANTIFUNGAL AGENTS; FUNGI; HUMANS; MYCOSES; PHARMACOLOGY; SYMBIOSIS;

EID: 84880098233     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.45     Document Type: Review

References (20)

1. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science 336, 647-647 (2012).
2. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nature Rev. Microbiol. 3, 547-556 (2005).
3. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology and consequences for treatment. Am. J. Med. 125, S3-S13 (2012).
4. Ericson E, Gebbia M, Heisler LE et al. Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet. 4(8), e1000151 (2008).
5. Giaever G, Flaherty P, Kumm J et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl Acad. Sci. USA 101, 793-798 (2004).
6. Ben-Ami R, Giladi M. Fluconazole-resistant Candida: collateral damage associated with prior antibacterial exposure? Future Microbiol. 7, 1029-1031 (2012).
7. Ferrari S, Ischer F, Calabrese D et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5, e1000268 (2009).
8. Thakur JK, Arthanari H, Yang F et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 452, 604-609 (2008).
9. Casadevall A, Pirofski LA. Exserohilum rostratum fungal meningitis associated with methylprednisolone injections. Future Microbiol. 8(2), 135-137 (2013).
10. ?rešnar B, Žakelj-Mavri? M. Aspects of the steroid response in fungi. Chem. Biol. Interact. 178, 303-309 (2009).
11. Banerjee D, Lelandais G, Shukla S et al. Responses of pathogenic and nonpathogenic yeast species to steroids reveal the functioning and evolution of multidrug resistance transcriptional networks. Eukaryot. Cell 7(1), 68-77 (2008).
12. Uesono Y, Araki T, Toh EA. Local anesthetics, antipsychotic phenothiazines, and cationic surfactants shut down intracellular reactions through membrane perturbation in yeast. Biosci. Biotechnol. Biochem. 72, 2884-2894 (2008).
13. Laggner C, Schieferer C, Fiechtner B et al. Discovery of high-affinity ligands of s(1) receptor, ERG2 and emopamil binding protein by pharmacophore modeling and virtual screening. J. Med. Chem. 48, 4754-4764 (2005).
14. Hull CM, Bader O, Parker JE et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob. Agents Chemother. 56, 6417-6421 (2012).
15. Kwon-Chung KJ, Chang YC. Aneuploidy and drug resistance in pathogenic fungi. PLoS Pathog. 8(11), e1003022 (2012).
16. Martel CM, Parker JE, Bader O et al. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54, 4527-4533 (2010).
17. Watson PF, Rose ME, Ellis SW, England H, Kelly SL. Defective sterol C5-6 desaturation and azole resistance-a new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164, 1170-1175 (1989).
18. Hull CM, Parker JE, Bader O et al. Facultative sterol uptake in an ergosteroldeficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 56(8), 4223-4232 (2012).
19. Healey KR, Katiyar SK, Raj S, Edlind TD. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86, 303-313 (2012).
20. Ribeiro R, Edvaldo A. Do Candida spp. "read" Nietzsche? Can xenobiotics modulate their aggressiveness? Proposition that chemicals may interfere in their virulence attributes. Mycopathologia 173(1), 69-71 (2012).